Class Action Lawsuit Compounds ImmunityBio's Regulatory and Legal Risks

What happened

Berger Montague PC announced a class action lawsuit against ImmunityBio for investors who purchased shares from January 19 to March 24, 2026, following an FDA warning letter on March 13 regarding promotional claims for ANKTIVA. The lawsuit alleges securities fraud, likely tied to misleading statements about compliance and sales practices, which the DeepValue report highlights as a key risk to commercial momentum. ImmunityBio's stock had surged on ANKTIVA's revenue growth but corrected sharply after the FDA action, now facing added legal scrutiny. This development underscores the company's existing challenges with high cash burn, reliance on external funding, and governance issues. The legal overhang threatens to distract from critical near-term catalysts, such as revenue growth and FDA remediation, intensifying operational pressures.

Implication

Legal proceedings could drain management attention and financial resources, hindering execution on revenue growth and regulatory containment. Potential settlements or penalties may strain cash flows, increasing reliance on dilutive financing from the $500M ATM program. Investor confidence may further erode, making equity raises more costly and challenging amid already tight funding conditions. The legal overhang could delay FDA remediation efforts and slow label expansion, such as the papillary NMIBC sBLA. Overall, this raises the probability of the bear case scenario where revenue stalls and heavy dilution occurs, undermining the investment thesis.

Thesis delta

The investment thesis for ImmunityBio was already cautious due to FDA promotional risks and funding dependencies, with a WAIT rating emphasizing near-term revenue and compliance checks. The class action lawsuit introduces additional legal uncertainty that could accelerate negative outcomes, such as reduced investor confidence and higher cost of capital. This reinforces the need for strict monitoring of Q1-Q2 2026 revenue growth and FDA remediation before any investment consideration.